Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacquelyn Klug-Mcleod

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry|September 12, 2015
Kinase hinge binding scaffolds and their hydrogen bond patternsLi Xing, Jacquelyn Klug-Mcleod, Brajesh Rai, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 15, 2012
The development of structure-activity relationships for mitochondrial dysfunction: uncoupling of oxidative phosphorylationRussell T Naven, Rachel Swiss, Jacquelyn Klug-McLeod, et al.
Journal of Computational Chemistry|December 6, 2022
Integrated design environment: A multi-use platform for design idea capture, evaluation, and tracking in medicinal chemistryMarian D Brodney, Gregory Bakken, Christopher R Butler, et al.
Chemical Research in Toxicology|February 16, 2010
Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibitionMichael Zientek, Chad Stoner, Robyn Ayscue, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Quick Building Blocks (QBB): An Innovative and Efficient Business Model To Speed Medicinal Chemistry Analog SynthesisChristopher J Helal, Mark Bundesmann, Susan Hammond, et al.
Bioorganic & Medicinal Chemistry Letters|November 17, 2012
Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitorsSamit K Bhattacharya, Gary E Aspnes, Scott W Bagley, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formationDaniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry|September 12, 2015
Kinase hinge binding scaffolds and their hydrogen bond patternsLi Xing, Jacquelyn Klug-Mcleod, Brajesh Rai, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 15, 2012
The development of structure-activity relationships for mitochondrial dysfunction: uncoupling of oxidative phosphorylationRussell T Naven, Rachel Swiss, Jacquelyn Klug-McLeod, et al.
Journal of Computational Chemistry|December 6, 2022
Integrated design environment: A multi-use platform for design idea capture, evaluation, and tracking in medicinal chemistryMarian D Brodney, Gregory Bakken, Christopher R Butler, et al.
Chemical Research in Toxicology|February 16, 2010
Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibitionMichael Zientek, Chad Stoner, Robyn Ayscue, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Quick Building Blocks (QBB): An Innovative and Efficient Business Model To Speed Medicinal Chemistry Analog SynthesisChristopher J Helal, Mark Bundesmann, Susan Hammond, et al.
Bioorganic & Medicinal Chemistry Letters|November 17, 2012
Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitorsSamit K Bhattacharya, Gary E Aspnes, Scott W Bagley, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formationDaniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Pageof 1